DMAC (STOCKS)
DiaMedica Therapeutics Inc. Common Stock
$5.630000
-0.020000 (-0.35%)
Prev close: $5.650000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Rick John Pauls
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $303.90M
- Employees
- 28
- P/E (TTM)
- -7.98
- P/B (TTM)
- 6.45
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
8
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.19 | $-0.19 | -0.0013 | -0.69% |
|
Dec 2025 (Q4)
|
$-0.17 | $-0.18 | +0.0136 | +7.41% |
|
Sep 2025 (Q3)
|
$-0.17 | $-0.16 | -0.0068 | -4.17% |
|
Jun 2025 (Q2)
|
$-0.18 | $-0.19 | +0.0138 | +7.12% |
Financial Statements
| Research and Development | $26.95M |
| Operating Income/Loss | -$36.74M |
| Income/Loss From Continuing Operations After Tax | -$35.10M |
| Income/Loss From Continuing Operations Before Tax | -$35.07M |
| Income Tax Expense/Benefit | $29.00K |
| Net Income/Loss | -$35.10M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$35.10M |
| Net Income/Loss Available To Common Stockholders, Basic | -$35.10M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.71 |
| Basic Average Shares | 148,193,256 |
| Assets | $53.08M |
| Current Assets | $52.36M |
| Cash | $51.30M |
| Other Current Assets | $1.06M |
| Noncurrent Assets | $717.00K |
| Fixed Assets | $142.00K |
| Other Non-current Assets | $575.00K |
| Liabilities | $5.85M |
| Current Liabilities | $5.75M |
| Accounts Payable | $3.29M |
| Wages | $741.00K |
| Other Current Liabilities | $1.71M |
| Noncurrent Liabilities | $97.00K |
| Equity | $47.24M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $47.24M |
| Liabilities And Equity | $53.08M |
| Net Cash Flow From Operating Activities | -$31.00M |
| Net Cash Flow From Operating Activities, Continuing | -$31.00M |
| Net Cash Flow From Investing Activities | -$10.93M |
| Net Cash Flow From Investing Activities, Continuing | -$10.93M |
| Net Cash Flow From Financing Activities | $44.20M |
| Net Cash Flow From Financing Activities, Continuing | $44.20M |
| Net Cash Flow | $2.28M |
| Net Cash Flow, Continuing | $2.28M |
| Comprehensive Income/Loss | -$35.11M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$35.13M |
| Other Comprehensive Income/Loss | -$27.41M |